Xer1-independent mechanisms of Vpma phase variation in Mycoplasma agalactiae are triggered by Vpma-specific antibodies
- PMID: 29122515
- DOI: 10.1016/j.ijmm.2017.10.005
Xer1-independent mechanisms of Vpma phase variation in Mycoplasma agalactiae are triggered by Vpma-specific antibodies
Abstract
Despite their small genomes mycoplasmas maintain large multigene families devoted to surface antigenic variation. Although implicated as important factors for mycoplasma pathogenicity and persistence, the role of these antigenic switches in host immune evasion has never been unequivocally proven in these minimalist microbes. Mycoplasma agalactiae exhibits antigenic variation due to Xer1-mediated site-specific DNA inversions of vpma genes encoding abundant multiple surface lipoproteins. To evaluate the biological significance of Vpma oscillations the xer1 recombinase gene has been disrupted in earlier studies to abolish Vpma switching and to generate stable phase-locked mutants (PLMs) steadily expressing a single Vpma product. However, in previous animal infection studies, surprisingly these PLMs switched to new different Vpma phenotypes. The aim of the current study was to demonstrate the influence of anti-Vpma antibodies on change of Vpma expression in PLMs as well as on the wildtype strain. In in vitro assays it is shown that wild type M. agalactiae escapes the negative effects of Vpma-specific antibodies by high-frequency Xer1-mediated switching to alternative Vpma phenoytpes. Even for Xer1-disrupted PLMs that stably expressed the same Vpma for several in vitro generations, the presence of the corresponding Vpma-specific antibody caused repression of the target Vpma and induction of new Vpma phenotypes by novel complex vpma rearrangements like intragenic deletions and gene chimeras. These Xer1-independent vpma recombinations correlated very well with similar PLM switches observed in vivo in an earlier independent study, clearly demonstrating that Vpma phase variation is necessary to express 'Vpma immune evasion proteins' in order to escape the immune response and to survive in the immunocompetent host. The data clearly demonstrate that although the Xer1 recombinase is the sole factor responsible for Vpma switching of wild type M. agalactiae in vitro, other alternative molecular switches operate in its absence under the selective pressure of the immune response. Furthermore, this evasion from the immune attack of the host involves complex vpma rearrangements, a causal relationship that was so far never demonstrated for M. agalactiae, thereby illustrating novel features of its regulation under immune pressure. The results are anticipated to have a direct impact on understanding the in vivo role of surface antigenic variation systems and the immune evasion tactics of other pathogenic mycoplasma species.
Keywords: Anti-Vpma antibodies; Antigenic switch mechanisms; Immune escape variants; Immune evasion; Mycoplasma agalactiae; Phase-locked mutants; Site-specific Xer1 recombinase; Vpma phase variation.
Copyright © 2017 The Authors. Published by Elsevier GmbH.. All rights reserved.
Similar articles
-
Vpma phase variation is important for survival and persistence of Mycoplasma agalactiae in the immunocompetent host.PLoS Pathog. 2017 Sep 28;13(9):e1006656. doi: 10.1371/journal.ppat.1006656. eCollection 2017 Sep. PLoS Pathog. 2017. PMID: 28957426 Free PMC article.
-
Phase-locked mutants of Mycoplasma agalactiae: defining the molecular switch of high-frequency Vpma antigenic variation.Mol Microbiol. 2008 Mar;67(6):1196-210. doi: 10.1111/j.1365-2958.2007.06103.x. Epub 2008 Jan 30. Mol Microbiol. 2008. PMID: 18248580 Free PMC article.
-
Xer1-mediated site-specific DNA inversions and excisions in Mycoplasma agalactiae.J Bacteriol. 2010 Sep;192(17):4462-73. doi: 10.1128/JB.01537-09. Epub 2010 Jun 18. J Bacteriol. 2010. PMID: 20562305 Free PMC article.
-
[Molecular basis of Mycoplasma agalactiae pathogenicity].Berl Munch Tierarztl Wochenschr. 2004 Nov-Dec;117(11-12):472-9. Berl Munch Tierarztl Wochenschr. 2004. PMID: 15584429 Review. German.
-
Phase and antigenic variation in mycoplasmas.Future Microbiol. 2010 Jul;5(7):1073-85. doi: 10.2217/fmb.10.71. Future Microbiol. 2010. PMID: 20632806 Review.
Cited by
-
Unveiling the stealthy tactics: mycoplasma's immune evasion strategies.Front Cell Infect Microbiol. 2023 Aug 31;13:1247182. doi: 10.3389/fcimb.2023.1247182. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37719671 Free PMC article. Review.
-
Predominant Single Stable VpmaV Expression in Strain GM139 and Major Differences with Mycoplasma agalactiae Type Strain PG2.Animals (Basel). 2022 Jan 21;12(3):265. doi: 10.3390/ani12030265. Animals (Basel). 2022. PMID: 35158589 Free PMC article.
-
Beware of Mycoplasma Anti-immunoglobulin Strategies.mBio. 2021 Dec 21;12(6):e0197421. doi: 10.1128/mBio.01974-21. Epub 2021 Nov 16. mBio. 2021. PMID: 34781733 Free PMC article. Review.
-
Comparative genomic analysis of Mycoplasma agalactiae strain GM139 highlights unique surface architecture and pathogenic determinants.Vet Res. 2025 May 24;56(1):106. doi: 10.1186/s13567-025-01531-x. Vet Res. 2025. PMID: 40413539 Free PMC article.
-
Serum Resistance of Mycoplasma agalactiae Strains and Mutants Bearing Different Lipoprotein Profiles.Pathogens. 2022 Sep 13;11(9):1036. doi: 10.3390/pathogens11091036. Pathogens. 2022. PMID: 36145468 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources